CompletedNCT00097266
Twelve-week aripiprazole treatment for mania in bipolarity
About this title
Read the official source — NCT00097266Medication studyAges 18+Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Anaheim and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 615
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00097266
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Anaheim, United States · Cerritos, United States · Garden Grove, United States
43 more locations
- National City, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Washington D.C., United States
- Maitland, United States
- Tampa, United States
- Shreveport, United States
- Albuquerque, United States
- Cleveland, United States
- Oklahoma City, United States
- DeSoto, United States
- Burgas, Bulgaria
- Novi Iskar, Bulgaria
- Pleven, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Osijek, Croatia
- Rijeka, Croatia
- Split, Croatia
- Zagreb, Croatia
- Zapopan, Mexico
- Mexico City, Mexico
- Col. Obispado, Mexico
- Monterrey, Mexico
- Fracc. Industrias, Mexico
- Mérida, Mexico
- Nuevo León, Mexico
- Lima, Peru
- Lipetsk, Russia
- Arkhangelsk, Russia
- Kazan', Russia
- Leningrad Region, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Volgograd, Russia
- Florida, South Africa
- Pretoria, South Africa
- Berea, South Africa
- Durban, South Africa
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Aripiprazole and Haloperidol.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
